Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,689 across all filing types
Latest filing 2022-08-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
创业板上市公司股权激励计划自查表
Regulatory Filings Classification · 95% confidence The document is a detailed compliance checklist related to a stock incentive plan for a listed company on the Growth Enterprise Market (创业板). It includes numerous compliance and regulatory checks, internal controls, and legal opinions related to the stock incentive plan. There is no indication that this is a financial report, earnings release, or management discussion. It is not a short announcement but a detailed compliance and regulatory document. The content aligns with regulatory filings related to compliance and disclosures rather than a formal report like an annual report or audit report. Therefore, the best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory compliance documents that do not fit other specific categories.
2022-08-11 Chinese
北京国枫律师事务所关于迪瑞医疗科技股份有限公司2021年限制性股票激励计划之回购注销部分限制性股票事项的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the repurchase and cancellation of restricted shares under a 2021 restricted stock incentive plan of a company. It details the legal compliance, approval procedures, and specifics of the repurchase price and quantity. It is not a financial report, earnings release, or management discussion. It is a legal proceeding related document providing legal opinions on a corporate action (stock repurchase and cancellation). Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length and content confirm it is a substantive legal opinion, not a brief announcement or certification.
2022-08-11 Chinese
迪瑞医疗：关于第五届董事会第六次会议相关事项的独立董事意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various board meeting matters, including capital changes, stock incentive plans, related party transactions, and foreign exchange business. It references compliance with stock exchange rules and company law, and it is dated August 10, 2022. The content is focused on governance and board-level approvals rather than financial results or audit findings. The document length is 3417 characters, which is relatively short and does not contain financial statements or detailed financial data. It is not a report itself but an official opinion related to board decisions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions from the board or senior management.
2022-08-11 Chinese
迪瑞医疗：关于公司开展远期外汇交易业务的可行性分析报告
Audit Report / Information Classification · 90% confidence The document is a detailed feasibility analysis report regarding the company's plan to engage in forward foreign exchange trading to hedge against currency risk. It includes background, purpose, risk analysis, and risk control measures. It is not a financial report like an annual or interim report, nor is it an announcement of voting results, management changes, or legal proceedings. It is a specific business activity analysis report related to capital risk management but does not fit into categories like Capital/Financing Update (CAP) which typically covers fundraising or capital structure changes. The document is a standalone report analyzing a specific financial risk management activity, which aligns best with Audit Report / Information (AR) as it involves risk assessment and internal control measures. The document length is under 5,000 characters but contains substantive content, so it is not a mere announcement. Therefore, the best fit is AR with high confidence. Q3 2022
2022-08-11 Chinese
关于公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of medical device registration certificates issued by regulatory authorities. It details specific product registrations and their intended uses, emphasizing the impact on the company's product portfolio and market competitiveness. There is no financial data, no mention of financial results, no discussion of management changes, no voting results, no legal proceedings, and no indication of a report or presentation. The document is a regulatory announcement about product certifications, which does not fit into financial report categories but is a regulatory filing informing the market about compliance and product approvals. The document length is short (2218 characters), and it is not an announcement of a report publication but a standalone announcement. Therefore, the best fitting category is Regulatory Filings (RNS).
2022-08-11 Chinese
关于回购注销部分限制性股票的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the repurchase and cancellation of restricted shares under a 2021 restricted stock incentive plan. It details the number of shares repurchased, the repurchase price, the approval process including board and shareholder meetings, and legal opinions. The document is a formal announcement of a share repurchase and cancellation event, not a full financial report or earnings release. It does not contain financial statements or earnings data but focuses on capital structure changes related to share repurchase and cancellation. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers company buybacks or sales of its own shares.
2022-08-11 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.